Treatment of multiple myeloma with the immunostimulatory SLAMF7 antibody elotuzumab.
Elotuzumab is a humanized monoclonal antibody targeting the extracellular domain of signaling lymphocytic activation molecule F7 (SLAMF7) highly expressed in multiple myeloma cells. Upon binding to myeloma cells, elotuzumab exerts its cytotoxic effects through antibody-dependent cellular cytotoxicity, the antibody-induced selective lysis of tumor cells by activated natural killer (NK) cells. Furthermore, elotuzumab has been shown to directly induce NK-cell activation by binding to SLAMF7 expressed on NK cells and to indirectly modulate T-cell function by promoting the secretion of cytokines from NK cells. In combination with lenalidomide and low-dose dexamethasone, elotuzumab has shown remarkable effects in patients with relapsed or refractory multiple myeloma. In these patients, the risk of disease progression or death was significantly reduced by 30% on elotuzumab. Currently, elotuzumab is being evaluated in various myeloma patient populations and combination regimens. This review discusses the use of elotuzumab as an antimultiple myeloma agent and provides an update on the results of recent clinical trials evaluating the safety and efficacy of elotuzumab for the treatment of multiple myeloma.
Medizinische Klinik und Poliklinik II, University of Wuerzburg, Oberduerrbacher Straße 6, Haus A3, 97080 Wuerzburg, Germany.
Hermann
H
Einsele
University Hospital Wuerzburg, Würzburg, Germany.
Martin
M
Schreder
CS1; SLAMF7; antibody-based immunotherapy; elotuzumab; multiple myeloma
Blood Lymphat Cancer. 2014 Jun;2014(4):15-27
26005365
Blood. 2002 Feb 1;99(3):754-8
11806974
Clin Cancer Res. 2014 Aug 1;20(15):3989-4000
24677374
Blood. 2008 Aug 15;112(4):1329-37
17906076
J Exp Med. 2014 Apr 7;211(4):727-42
24687958
Leukemia. 2012 Feb;26(2):199-213
21852787
Lancet Haematol. 2015 Dec;2(12):e516-27
26686406
Cancer Immunol Immunother. 2015 Jan;64(1):61-73
25287778
Mol Cancer Ther. 2001 Nov;1(1):69-78
12467240
Cancer Res. 2007 Mar 15;67(6):2783-90
17363600
Crit Rev Oncol Hematol. 2013 Oct;88(1):168-77
23731618
Leukemia. 2014 Apr;28(4):917-27
24067492
Mol Cancer Ther. 2009 Sep;8(9):2616-24
19723891
Mol Cell Biol. 2015 Jan;35(1):41-51
25312647
J Immunol. 2007 Oct 1;179(7):4672-8
17878365
Arch Biochem Biophys. 2012 Oct 15;526(2):146-53
22387378
Crit Rev Oncol Hematol. 2015 Dec;96(3):399-412
26153389
Lancet. 2009 Jul 25;374(9686):324-39
19541364
Semin Oncol. 2013 Oct;40(5):618-33
24135407
N Engl J Med. 2015 Aug 13;373(7):621-31
26035255
J Clin Oncol. 2012 Jun 1;30(16):1953-9
22547589
N Engl J Med. 2007 Nov 22;357(21):2133-42
18032763
Blood Cancer J. 2015 Aug 07;5:e334
26252787
Cancer Immunol Immunother. 2013 Dec;62(12 ):1841-9
24162108
Clin Cancer Res. 2008 May 1;14 (9):2775-84
18451245
Clin Adv Hematol Oncol. 2015 Sep;13(9):599-609
26452191
Oncogene. 2015 Sep 3;34(36):4673-82
25639873
Annu Rev Immunol. 2011;29:665-705
21219180
CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29
25559415
J Clin Oncol. 2012 Jun 1;30(16):1960-5
22291084
Blood. 2012 Jul 19;120(3):552-9
22184404
J Immunol. 2008 Jan 1;180(1):163-70
18097016
Clin Lymphoma Myeloma Leuk. 2016 Mar;16(3):129-38
26795075
Clin Cancer Res. 2003 Mar;9(3):1145-54
12631620
Leukemia. 2014 Mar;28(3):525-42
24253022
J Clin Oncol. 2008 Mar 20;26(9):1544-52
18285605
J Clin Oncol. 2003 Nov 1;21(21):3940-7
12975461
Br J Haematol. 2011 Sep;154(6):745-54
21777223